While TP53 mutations are found with a low incidence at diagnosis, their incidence rises in refractory CLL, making the disruption of the TP53 gene the most important predictive biomarker in CLL [8,9]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.